A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities

Alexey V. Danilov, Lionel D. Lewis, Frederick Lansigan, Liya Roudaia, Darcie L. Findley, Susan Y. Jones, Brian Highhouse, Bernard B. Beaulieu, Jennifer R. Brown

Research output: Contribution to journalLetter

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)820-823
Number of pages4
JournalBritish Journal of Haematology
Volume178
Issue number5
DOIs
StatePublished - Sep 2017

Keywords

  • bendamustine
  • chronic lymphocytic leukaemia
  • comorbidities

ASJC Scopus subject areas

  • Hematology

Cite this

Danilov, A. V., Lewis, L. D., Lansigan, F., Roudaia, L., Findley, D. L., Jones, S. Y., Highhouse, B., Beaulieu, B. B., & Brown, J. R. (2017). A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities. British Journal of Haematology, 178(5), 820-823. https://doi.org/10.1111/bjh.14171